Table 1

Baseline characteristics of the cohort

Total cohort n=25Responders n=12Non-responders n=11P value
Demographics
 Age (years, mean±SD)73.4±10.068.1±14.476.0±7.40.19
 Male (n,%)23 (92.0%)12 (100.0%)9 (81.8%)0.42
Device
 CRT-D (n,%)18 (72.0)8 (66.7)9 (81.8)0.73
 Upgrade (n,%)9 (36.0)2 (16.7)7 (63.6)0.06
Aetiology
 Ischaemic (n,%)16 (64.0)6 (50.0)8 (72.7)0.49
 Non-ischaemic (n,%)9 (36.0)6 (50.0)3 (27.3)
Comorbidities
 Diabetes mellitus (n,%)6 (24.0)2 (16.7)4 (36.4)0.55
 CKD (n,%)13 (52.0)7 (58.3)6 (54.5)1.00
NYHA (n,%)
 II10 (43.5)5 (41.7)5 (45.5)0.52
 III12 (52.2)7 (58.3)5 (45.5)
 IV1 (4.3)0 (0.0)1 (9.1)
ECG
 AF (n,%)9 (36.0)4 (33.3)4 (36.4)1.00
 LBBB (n,%)17 (68.0)9 (75.0)6 (54.5)0.56
 QRS (ms, median, range)162(120–212)168 (138–212)160 (138–194)0.60
 6MWT (M, mean±SD)252.6±132.0291.9±133.3215.3±147.40.29
QOL score (median, range)48.0 (8.0–85.0)55.5 (9.0–85.0)29.0 (8.0–68.0)0.11
Laboratory tests
 eGFR (ml/min/1.73 m2, median, range)52.0 (25.0–130.0)52.5 (25.0–130.0)52.0 (26.0–79.0)0.61
 NT-pro-BNP (pmol/L, median, range)267.0 (75.0–4138.0)237.0 (75.0–4138.0)273.0 (133.0–547.0)0.33
Medications
 ACEi/ARB (n,%)25 (100.0)12 (100.0)11 (100.0)1.00
 BB (n,%)21 (84.0)10 (83.3)10 (90.9)0.62
 MRA (n,%)14 (56.0)7 (58.3)5 (45.5)0.38
Echocardiography*
 LVESV (mL, median, range)125.8 (62.9–268.7)136.7 (80.7–268.7)110.9 (62.9–169.4)0.29
 LVESV_BSA(mL, median, range)58.9 (38.7–128.0)66.1 (42.7–128.0)59.1 (38.7–85.8)0.35
 LVEF (%, median, range)25.6 (9.7–35.4)24.4 (10.0–34.4)28.6 (9.7–35.4)0.40
Body composition
 BMI (kg/m2, median, range)28.7 (22.4–41.9)29.3 (22.4–37.3)27.8 (23.9–40.8)0.85
 FM (kg, median, range)31.4 (18.1–61.2)31.3 (19.3–56.4)29.7 (18.1–58.7)0.81
 Relative FM (median, range)0.38 (0.23–0.54)0.35 (0.28–0.50)0.42 (0.23–0.54)0.29
 Lean mass (kg, median, range)52.3 (30.9–73.3)52.6 (40.3–73.3)50.5 (30.9–62.5)0.48
 Waist (cm, median, range)98.2 (84.6–131.0)97.5 (84.6–120.8)98.2 (85.0–114.5)0.79
  • *Based on available data

  • ACEi, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, ACE receptor antagonist; BMI, body mass index; BNP, brain natriuretic peptide; BSA, body surface area; CKD, chronic kidney disease; CRT, cardiac resynchronisation therapy; eGFR, estimated glomerular filtration rate; FM, fat mass; LBBB, Left bundle branch block; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; 6MWT, 6 min walk test; NT-pro-BNP, N-terminal probrain natriuretic peptide; NYHA, New York Heart Failure Assessment; QOL, quality of life; QRS, QRS width on ECG.